Although the prognosis of clear cell sarcoma of the kidney (CCSK) has improved, when metastases occur the probability of cure is very low. We have treated two pediatric patients with relapsed CCSK, one with multiple bone metastases and another with brain metastases. After one or two courses of re-induction chemotherapy and radiation therapy to the sites of metastasis, they received double high-dose chemotherapy with autologous bone marrow rescue. Conditioning regimens were ifosphamide plus melphalan for the first autograft and busulfan plus thiotepa for the second. Hematological recovery was prompt, and no severe complications were observed. They are doing well without evidence of recurrence at 19 and 49 months after the second autograft, respectively. Keywords: clear cell sarcoma of the kidney (CCSK); bone marrow transplantation; childhood Clear cell sarcoma of the kidney (CCSK) was first described by Kidds 1 in 1970, and its histologic characteristics were defined thereafter.
Clear cell sarcoma of the kidney (CCSK) was first described by Kidds 1 in 1970, and its histologic characteristics were defined thereafter. 2, 3 It was also called bonemetastasizing renal tumor of childhood by Marsden et al 2 due to its unusual pattern of spread.
Investigation of the efficacy of therapies for CCSK in the National Wilms' Tumor Study (NWTS)-1, NWTS-2 and NWTS-3 revealed that addition of doxorubicin to the combination of vincristine plus dactinomycin improved the 6-year relapse-free survival rate of this tumor. 3 However, about one-third of children with CCSK died due to treatment failure. The prognosis for relapsed cases is very poor and no convincing treatment strategy has been thus far established. 4 We present two patients with CCSK relapsing during the treatment of NWTS-3 who received intensive treatments including double autografts. They have remained in second remission longer than first remission. 
Case reports

Case 1
A 22-month-old boy presented in April 1992 with a history of vomiting and abdominal distention. A CT scan showed a large mass in the left renal fossa. Bone marrow aspiration, CT scan of the lung and brain, and bone scintigrams showed no metastases. A left radical nephrectomy was carried out and the resected kidney contained a large tumor which weighed 710 g and measured 11.2 × 11 × 8.9 cm. Microscopic examination showed nests or cords of cells separated by a network of small capillaries. The nuclei of the tumor cells were finely granular, imparting an 'empty' appearance compatible with CCSK.
Chemotherapy consisting of 10 doses of vincristine (VCR) weekly, 5 days of dactinomicin (AMD) in the first week and 3 days of doxorubicin (DOX) in the sixth week, and two alternating sequences: AMD on days 1-5 combined with VCR on days 1 and 5, and DOX on days 1-3 repeated every 6 weeks for 65 weeks was started on 19 May 1992 after 10.5 Gy of radiation to the left abdomen. In February 1993, tumors of the skull were detected, and bone scintigrams revealed multiple high-uptake regions, three in the skull (frontal and left parietal bones) and one in the distal end of the left femur. X-ray of the left femur showed a large defect of the bone with a fracture at the distal end. A CT scan of the lung, ultrasound examination of the abdomen and bone marrow aspiration revealed no other sites of metastasis. Chemotherapy consisting of 100 mg/m 2 of etoposide (VP-16), 10 mg/m 2 of 4′-O-tetrahydropyranyladriamycin (THP) and 20 mg/m 2 of cisplatin (CDDP) on days 1-5 was started, and the size of the tumors in the skull reduced promptly. After one course of chemotherapy, his unpurged marrow was collected and stored. Twenty-five Gy of radiation were given to the regions of the skull and femur after two courses of chemotherapy. He underwent double high-dose chemotherapy with autologous bone marrow rescue in June and September of 1993. Conditioning regimens were ifosphamide (IFO) plus melphalan (L-PAM) for the first autograft, and busulfan (BU) plus thiotepa (TT) for the second one, as shown in Table 1 . Biopsy of the frontal bone was carried out in July 1993, but no viable tumor cells were detected. Hematological recovery was prompt and no severe complications were observed ( Table 1 ). The patient is in complete remission more than 49 months after the second megatherapy. The NWTS-III study demonstrated that chemotherapy consisting of AMD, VCR and DOX, with addition of radiation therapy to the tumor bed, improved the 6-year survival rate up to 71.9%. 3 However, cure of relapsed cases is very difficult, and 3-year survival after relapse in Wilms' tumors with unfavorable histology is only 7-15%. 4 We treated two relapsed cases with intensive treatments including double autografts. High-dose chemotherapy with autologous bone marrow transplantation (ABMT) has been performed for advanced or relapsed malignant solid tumors in children. However, the efficacy of high-dose chemotherapy for Wilms' tumors with unfavorable histology remains unclear. The European Bone Marrow Transplantation Solid Tumor Registry presented 25 cases with a relapsed Wilms' tumor who received high-dose therapy followed by ABMT. 5 The report included six cases with an unfavorable histology, but their precise histologic types were not shown. Only one case with an unfavorable histology is alive without recurrence at 36 months after ABMT. More recently, a Swedish group reported four cases of relapsed Wilms' tumor including one case of CCSK treated by ABMT, and the case of CCSK sustained a further relapse. 6 Which agents other than dactinomycin, VCR and DOX are effective for CCSK? A phase II trial of IFO and VP-16 in relapsed cases suggested its efficacy. 7 In the present cases, chemotherapy consisting of THP, VP-16 and CDDP reduced the size of tumors in the skull of case 1. Although the effects of CBDCA and CDDP on CCSK are obscure, our findings suggest that combination with THP, VP-16 and CDDP may be effective for CCSK. We have used L-PAM, IFO, TT and BU in double grafts for high-risk neuroblastoma without severe complications, and obtained good results. 8 The efficacy of these agents, other than IFO, for CCSK is unknown. However, L-PAM has been widely used for pediatric malignancies, and looks promising. High-dose TT has also recently been used for both adult and pediatric malignancies, such as melanoma, lymphoma, breast cancer, neuroblastoma and leukemia. Saarinen et al 9 reported that one relapsed case of Wilms' tumor with unfavorable histology achieved complete remission after high-dose TT with ABMT. High-dose therapy with BU combined with cyclophosphamide is usually used for hematological malignancies. The results of a phase II study of this therapy for pediatric solid tumors showed efficacy in neuroblastoma, non-Hodgkin's lymphoma and rhabdomyosarcoma. 10 Although Wilms' tumors were not included in the report, BU is suggested to be a useful agent for pediatric malignant solid tumors. Based on these findings and our experience, we performed double grafts in the present cases. Since late relapse in cases with CCSK have been reported, longer follow-up is required to prove cure. However, complete remission has continued for more than 4 years in one of the present cases and the remission duration of the other case exceeds his first remission period. We suggest that this strategy is a good one for CCSK.
